文献速递艾滋病与性传播感染

Vesatolimod(TLR7激动剂)在病毒抑制的HIV-1感染者中诱导免疫激活

Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1.
PubMed 文献 · Clin Infect Dis · 2021-01-01

这项双盲、多中心、安慰剂对照的Ib期研究纳入48名接受抗逆转录病毒治疗且血浆HIV-1 RNA<50拷贝/mL的HIV-1感染者,按6:2随机接受6-10剂Vesatolimod(1-12 mg)或安慰剂,每两周口服一次。Vesatolimod总体耐受良好,未出现研究药物相关严重不良事件或导致停药的不良事件;各剂量组血浆HIV-1 RNA较基线无统计学显著变化;剂量>4 mg时观察到细胞因子、干扰素刺激基因表达和淋巴细胞激活的一致反应。

要点

  • Vesatolimod 1-12 mg每两周口服耐受良好,无药物相关严重不良事件。
  • 各剂量组血浆HIV-1 RNA较基线无统计学显著变化。
  • 剂量>4 mg时观察到免疫激活反应,支持未来联合试验。

核心结论

  • Vesatolimod在1-12 mg剂量范围内耐受良好,>4 mg剂量可诱导免疫激活,为未来在HIV感染者中开展联合试验提供依据。

研究设计与样本

  • 双盲、多中心、安慰剂对照的Ib期研究,48名接受抗逆转录病毒治疗且筛查血浆HIV-1 RNA<50拷贝/mL的HIV-1感染者按6:2随机接受Vesatolimod(n=36)或安慰剂(n=12)。
  • 受试者每两周口服6-10剂Vesatolimod(1-12 mg)或匹配安慰剂,采用序贯剂量递增队列。

主要发现

  • Vesatolimod总体耐受良好,未出现研究药物相关严重不良事件或导致研究药物停用的不良事件。
  • 与安慰剂相比,Vesatolimod组血浆HIV-1 RNA较基线无统计学显著变化。
  • Vesatolimod血浆暴露随剂量成比例增加;剂量>4 mg时观察到细胞因子、干扰素刺激基因表达和淋巴细胞激活的一致反应。
  • 6 mg剂量后24小时,干扰素γ诱导蛋白10(IP-10)、白介素-1受体拮抗剂(IL-1RA)、干扰素诱导T细胞α趋化因子(ITAC)的峰值升高较基线>3.9倍。

临床怎么用

  • Vesatolimod 1-12 mg每两周口服在病毒抑制的HIV-1感染者中耐受良好,但当前数据不支持其单药对血浆HIV-1 RNA的显著影响。
  • 剂量>4 mg可诱导免疫激活,可考虑作为未来联合治疗试验的剂量选择参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment with vesatolimod, an investigational, oral, toll-like receptor 7 (TLR7) agonist, leads to sustained viral remission in some non-human primates when combined with anti-envelope antibodies or therapeutic vaccines. We report results of a Phase Ib study evaluating safety, pharmacokinetics, and pharmacodynamics of vesatolimod in adults living with human immunodeficiency virus (HIV)-1. METHODS: In this double-blind, multicenter, placebo-controlled trial, participants on antiretroviral therapy with screening plasma HIV-1 RNA levels <50 copies/mL were randomized (6:2) to receive 6-10 doses of vesatolimod (1-12 mg) or matching placebo orally every other week in sequential dose-escalation cohorts. The primary study objectives included establishing the safety and virologic effects of vesatolimod (change from baseline in plasma HIV-1 RNA). Pharmacokinetics and pharmacodynamic/immunologic activity were assessed as secondary objectives. RESULTS: A total of 48 individuals were randomly assigned to vesatolimod (n = 36) or placebo (n = 12). Vesatolimod was generally well tolerated, with no study drug-related serious adverse events or adverse events leading to study drug discontinuation. There were no statistically significant changes from baseline in plasma HIV-1 RNA in the vesatolimod groups, compared to placebo.Vesatolimod plasma exposures increased dose proportionally; consistent responses in cytokines, interferon-stimulated gene expression, and lymphocyte activation were observed with increasing dose levels above 4 mg. Peak elevations 24 hours after receipt of a 6 mg dose were >3.9-fold higher for interferon gamma-induced protein 10 (IP-10), interleukin-1 receptor antagonist (IL-1RA), interferon-inducible T-cell alpha chemoattractant (ITAC) when compared to baseline values. CONCLUSIONS: Vesatolimod was well tolerated at doses ranging from 1 to 12 mg. Immune stimulation was observed at doses above 4 mg, providing rationale for future combination trials in people living with HIV. CLINICAL TRIALS REGISTRATION: NCT02858401.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Riddler SA, Para M, Benson CA, et al. Vesatolimod, a Toll-like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults Living With Human Immunodeficiency Virus-1. Clin Infect Dis. 2021. PMID: 33043969. doi:10.1093/cid/ciaa1534

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。